All Rituxan news

2 hours ago Why Halozyme Therapeutics, Inc. Stock Soared 39.6% in November - FOX Business
2 hours ago Why Halozyme Therapeutics, Inc. Stock Soared 39.6% in November - FOX Business
22 hours ago Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan - Business Wire
2 days ago Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting - Business Wire
5 days ago Genentech’s Ocrevus Pioneering The Progressive MS Therapy Landscape - PharmaceuticalOnline
5 days ago Despite the number of Americans living with ME/CFS, little is known about the debilitating illness - Pittsburgh City Paper
13 days ago Medical Mystery: A persistent headache turns out to be something ominous - Guelph Mercury
21 days ago Why the cost of your health insurance will rise in 2017 - CBC.ca

Create a custom search

News search supports Google type search formatting and the use of complex boolean. Wrap terms in double quotes for exact phrase matching. Click + to add multiple news search terms to this topic.